These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 19672905)

  • 1. Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo.
    Redmond WL; Gough MJ; Weinberg AD
    Eur J Immunol; 2009 Aug; 39(8):2184-94. PubMed ID: 19672905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist.
    Redmond WL; Gough MJ; Charbonneau B; Ratliff TL; Weinberg AD
    J Immunol; 2007 Dec; 179(11):7244-53. PubMed ID: 18025166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.
    Redmond WL; Triplett T; Floyd K; Weinberg AD
    PLoS One; 2012; 7(4):e34467. PubMed ID: 22496812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
    Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
    Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo antitumor function of tumor antigen-specific CTLs generated in the presence of OX40 co-stimulation in vitro.
    Pham Minh N; Murata S; Kitamura N; Ueki T; Kojima M; Miyake T; Takebayashi K; Kodama H; Mekata E; Tani M
    Int J Cancer; 2018 Jun; 142(11):2335-2343. PubMed ID: 29313971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
    Redmond WL; Linch SN; Kasiewicz MJ
    Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OX40 and Bcl-xL promote the persistence of CD8 T cells to recall tumor-associated antigen.
    Song A; Tang X; Harms KM; Croft M
    J Immunol; 2005 Sep; 175(6):3534-41. PubMed ID: 16148096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses.
    Ruby CE; Redmond WL; Haley D; Weinberg AD
    Eur J Immunol; 2007 Jan; 37(1):157-66. PubMed ID: 17183611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracellular Galectin-3 Is Essential for OX40-Mediated Memory CD8
    Amani MF; Rolig AS; Redmond WL
    J Immunol; 2020 Oct; 205(7):1857-1866. PubMed ID: 32848035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen.
    Murata S; Ladle BH; Kim PS; Lutz ER; Wolpoe ME; Ivie SE; Smith HM; Armstrong TD; Emens LA; Jaffee EM; Reilly RT
    J Immunol; 2006 Jan; 176(2):974-83. PubMed ID: 16393983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
    Moran AE; Polesso F; Weinberg AD
    J Immunol; 2016 Sep; 197(6):2509-21. PubMed ID: 27503208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing the Generation of Eomes
    Emerson DA; Rolig AS; Redmond WL
    Cancer Immunol Res; 2021 Apr; 9(4):430-440. PubMed ID: 33593794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-12 is required for anti-OX40-mediated CD4 T cell survival.
    Ruby CE; Montler R; Zheng R; Shu S; Weinberg AD
    J Immunol; 2008 Feb; 180(4):2140-8. PubMed ID: 18250420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells.
    Takeda I; Ine S; Killeen N; Ndhlovu LC; Murata K; Satomi S; Sugamura K; Ishii N
    J Immunol; 2004 Mar; 172(6):3580-9. PubMed ID: 15004159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of A1 by OX40 contributes to CD8(+) T cell survival and anti-tumor activity.
    Lei F; Song J; Haque R; Haque M; Xiong X; Fang D; Croft M; Song J
    PLoS One; 2013; 8(8):e70635. PubMed ID: 23936461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD134 Costimulation Couples the CD137 Pathway to Induce Production of Supereffector CD8 T Cells That Become IL-7 Dependent.
    Lee SJ; Rossi RJ; Lee SK; Croft M; Kwon BS; Mittler RS; Vella AT
    J Immunol; 2007 Aug; 179(4):2203-14. PubMed ID: 17675480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional similarity and differences between selection-independent CD4-CD8- alphabeta T cells and positively selected CD8 T cells expressing the same TCR and the induction of anergy in CD4-CD8- alphabeta T cells in antigen-expressing mice.
    Caveno J; Zhang Y; Motyka B; Teh SJ; Teh HS
    J Immunol; 1999 Aug; 163(3):1222-9. PubMed ID: 10415017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costimulation of CD8 T cell responses by OX40.
    Bansal-Pakala P; Halteman BS; Cheng MH; Croft M
    J Immunol; 2004 Apr; 172(8):4821-5. PubMed ID: 15067059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of OX40-mediated co-stimulation in T-cell activation and survival.
    Redmond WL; Ruby CE; Weinberg AD
    Crit Rev Immunol; 2009; 29(3):187-201. PubMed ID: 19538134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo.
    De Smedt T; Smith J; Baum P; Fanslow W; Butz E; Maliszewski C
    J Immunol; 2002 Jan; 168(2):661-70. PubMed ID: 11777959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.